MDSpire - Summary
Clinical Guidelines
Commentary & Perspectives

Industry Insights: Genomic Testing for Early-Stage Breast Cancer

William Audeh, Chief Medical Officer at Agendia, discusses recent data supporting genomic testing results in guiding clinical decision-making

  • March 27, 2026

  • 8 min

Share

Genomic assays are revolutionizing decision-making in early-stage breast cancer by focusing on the tumor's intrinsic biology rather than solely on traditional clinicopathologic factors. These molecular tests, such as the 80-gene molecular subtyping and 70-gene risk-of-recurrence tests, identify patients who will benefit from adjuvant chemotherapy. Notably, studies like MINDACT and FLEX provide evidence for personalizing treatment plans based on genomic risk profiles, helping to spare low-risk patients from unnecessary chemotherapy while enhancing surgical decision-making.

Original Source(s)

Industry Insights: Genomic Testing for Early-Stage Breast Cancer

  • March 27, 2026

Related Content

Recipients Named for the 2026 Pezcoller Foundation–AACR International Award

The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Douglas R. Lowy, MD, and John T. Schi...

AI As Collaborator in Cancer Research and in Clinical Care

Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identif...

AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?

The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New E...